Clinical Trial Update: Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of oxaliplatin and sorafenib for advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma that…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Nexavar (Sorafenib)

Snippet

Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo | Conditions: Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment) | Phase 2 | Status: COMPLETED